0,1,2,3,4
"Viruses 2014, 6",,,,
,,,Table 1. Cont.,
MVA vaccine,Response,Model,Protective efficacy after challenge,Literature
,B cells and T,,,
MVA-NP,,mice,Heterologous protection,[127]
,cells,,,
,,mice,Partial heterologous protection*,"[123,125]"
,,chickens,Heterologous protection*,"[124,125]"
MVA-NP+M1,T cells,,,
,,pigs,Not tested with challenge,[125]
,,humans,"Intrasubtypic protection, safe in elderly","[119â€“122,126]"
MVA-M1,**,mice,No protection,[127]
MVA-M2,**,mice,No protection,[127]
MVA-PB1,,mice,No protection,[127]
MVA-HA-Eq/Ky81,HA: B-cells,,,
,,,HA: Homologous protection,
(A/Equine/Kentuck,,,,
,,horses,NP: Partial homologous protection,[128]
y/1/81),,,,
,,,Literature:,
MVA-NP-Eq/Ky81,not tested,,,
,* In combination with Adenovirus vaccine. ** No protective antibody response or T cell response measured.,,,
